COVID-19 Records

Email

Gates Package, pp.469-472 · gates:email:00378

Page text: p.469, p.470, p.471, p.472 · original PDF

Date
(unknown precision)
Type
email · email
sender
Robert Hiouail Nin. Gov Eiss
to
Albert, Rand Paul, Blithe, Diana
Topics
Gates Foundation involvementIntelligence community assessmentsTherapeutics and treatments
exchange.nih.gov>, "Brewinski Isaacs, Maggie (NIH/NICHD) [E]" )mail.nih.gov>, "Freund, Lisa (NIH/NICHD) [E]" )mail.nih.gov>, "Hazra, Rohan (NIH/NICHD) [E]" mail.nih.gov>, "Tlekis, John (NIH/NICHD) [E]" [@mail.nih.gov>, "Krotoski, Danuta (NIH/NICHD) [E]" mail. nih.gov>, "Lee, Sonia (CHD) [E]" BE nit cov>, "Moss, Stuart (NIH/NICHD) [E]" )mail.nih.gov>, "Newcomer, Susan (NIH/NICHD) [E]" exchange.nih.gov>, "Raiten, Daniel (NIH/NICHD) [E]" )mail. nih.gov>, "Reddy, Uma TCHD) [E]" BEB omnait nin. gov>, "Signore, Caroline (NIH/NICHD) [E]" )mail.nih.gov>, "Barry, Clifton (NIWNIADD) [E]" [oniaid.nib.gov>, "Boyce, Jim TAID) [E]" jnih.gov>, "Cassels, Fred (NIH/NIAID) [E]" niaid.nih.gov>, "Datta, Sandi TAID) [E]" BEB oniaicnin gov>, "Green, Kim (NIH/NIAID) [E]" niaid.nih.gov>, "Hall, Lee (NIH/NIAID) [E]" niaid.nih.gov>, "Koso-Thomas, Marion (NIH/NICHD) [E]" pe eee "Kurilla, Michael (NIW/NIAID) [E]" Mo vicidatanon "Lacourciere, Karen (NIH/NIAID) [E]" niaid.nih.gov>, "Lambert, Linda (NIH/NIAID) [E]" \niaid.nih.gov>, "Ledgerwood, Julie (NIH/NIAID) [E]" niaid.nih.gov>, "Marovich, Mary (NIH/NIAID) [E]" mnih.gov>, "Marston, Hilary (NIH/NIAID) [E]" 'ih.gov>, "Mascola, John (NIH/VRC) [E]" mail.nih.gov>, "Zwerski, Sheryl )) [E]" WIM wisch goo "Kreimer, Aimee (NIH/NCD [E]" Rone ane "Schiffman, Mark (NIH/NCI) [E]" exchange.nih.gov>, "Pringle, Beverly (NIH/NIMH- " mail.nih.gov>, "Buckley, Shu (NIH/NIMH) [E]" \nih.gov>, "Rosenthal, Josh P. (NIH/FIC) [E]" )ficod.fic.nih.gov>, "Gottlieb, Michael (ENTE) [T]" --fnih.org>, "Kurilla, Michael (NIH/NIAID) [E]" idee "Rao, Malla (NIH/NIAID) [E]" niaid.nih.gov>, "Costero-Saint Denis, Adriana TAID) [E]" niaid.nih.gov>, "Deye, Greg (NIH/NIAID) [E]" Oni oc "Mcgugan, Glen (NIH/NIAID) [E]" em "Handley, Gray (NIH/NIAID) [E]" niaid.nih.gov> Ce: "Kline, Lydia (NIH/FIC) [C]" [@nih.gov>, "Weymouth, Kristen (NIH/FIC) [E]" mail.nih.gov>, "Wan. ane: iG) [e]" BE vit cov>, "Officer, Jackie (NIH/FIC) [E]" nih.gov> Subject: NIH-Gates Foundation Workshop, July 8: Agenda and list of participants Date: Wed, 01 Jul 2015 17:08:29 -0400 Importance: Normal Attachments: BMGF-NIH_Second_Annual_ Meeting (7.1).docx; NIHBill_& Melinda_Gates_Foundation_Participant_List_July_Workshop_7.1.docx Dear Colleagues, We look forward to your participation the NIH-Bill & Melinda Gates Foundation Workshop next week _| attach the current agenda and list of Gates Foundation and NIH participants. There may be a few late confirmations and/or needed corrections. A final list of participants will be available at the meeting I also will send on any pre-reads suggested by any of the working group co-chairs. Please don't hesitate to contact me with and questions _If needed, my cell is TE -'-- Best regards Bill & Melinda Gates Foundation-NIH Second Annual Consultative Workshop July 8, 2015 John Edward Porter Neuroscience Research Center (Building 35A) NIH Campus, Bethesda, Maryland 8:30 AM - 8:40 AM Welcome -- Francis Collins, Trevor Mundel 8:40 AM - 9:30 AM Drug Repurposing and Global Health: Accelerating the Pace. Co-Moderators: Dr. Chris Austin, NCATS; Dr. Trevor Mundel, BMGF The session will focus on innovations in early and late stage drug repurposing, and relevance to priority therapeutics for global health. Priority topics include: • accessing data & compounds from innovator firms • corporate incentives and models of collaboration • creative IP management • crowdsourcing and clearinghouses • support for Phase IIb and III 9:30 AM - 10:30 AM Research Preparedness and Lessons Learned from the Ebola Outbreak Co-moderators: Dr Cliff Lane, NIAID; Alan Magill, BMGF The session will take stock of the challenges encountered in responding to microbial outbreaks, based on the recent experience with Ebola epidemic. The aim is to understand generalizable lessons from this response, and explore ways to most effectively address future outbreaks. Priority topics include: • clinical trial design • implementing clinical trials • developing protocols and guidance for research studies in advance • sharing of specimens and data, and access to specialized reagents • community engagement • coordination and real-time, open sharing of information across diverse disciplines • challenges of implementing rapid funding 10:30 AM - 10:45 AM Coffee break se Priorities